Nuzenio

Pharmanovia

Pharmanovia news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 9 publisher sources 100/100 entity strength

Latest news

IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib - Pharmaceutical TechnologyPharmaceutical Technology · Mon, 03 Aug 2026 11:22:18 GMT IMPACT licenses ovarian cancer drug senaparib to Pharmanovia - The Pharma LetterThe Pharma Letter · Mon, 03 Aug 2026 09:00:51 GMT IMPACT Therapeutics Partners with Pharmanovia to Commercialise Senaparib Across Europe, MENA, Australia and New Zealand - BioPharma APACBioPharma APAC · Sun, 02 Aug 2026 18:34:30 GMT Pharmanovia to pay IMPACT over €420M for certain rights to oral PARP1/2 inhibitor senaparib - FirstWord PHARMAFirstWord PHARMA · Fri, 31 Jul 2026 15:36:36 GMT Pharmanovia licenses China-approved PARP drug for up to €423.5M - European Biotechnology MagazineEuropean Biotechnology Magazine · Fri, 31 Jul 2026 13:54:45 GMT IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand - marketscreener.commarketscreener.com · Fri, 31 Jul 2026 10:50:46 GMT IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand - V-news.itV-news.it · Fri, 31 Jul 2026 08:04:00 GMT IMPACT Therapeutics Strikes EUR423.5 Million Global Senaparib Deal With Pharmanovia - TipRanksTipRanks · Thu, 30 Jul 2026 10:50:04 GMT

Timeline

Mon, 03 Aug 2026 11:22:18 GMTIMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib - Pharmaceutical Technology

Mon, 03 Aug 2026 09:00:51 GMTIMPACT licenses ovarian cancer drug senaparib to Pharmanovia - The Pharma Letter

Sun, 02 Aug 2026 18:34:30 GMTIMPACT Therapeutics Partners with Pharmanovia to Commercialise Senaparib Across Europe, MENA, Australia and New Zealand - BioPharma APAC

Fri, 31 Jul 2026 15:36:36 GMTPharmanovia to pay IMPACT over €420M for certain rights to oral PARP1/2 inhibitor senaparib - FirstWord PHARMA

Fri, 31 Jul 2026 13:54:45 GMTPharmanovia licenses China-approved PARP drug for up to €423.5M - European Biotechnology Magazine

Fri, 31 Jul 2026 10:50:46 GMTIMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand - marketscreener.com

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.

Connected entities

IMPACT4 live mentions Europe4 live mentions Australia4 live mentions North Africa4 live mentions IMPACT Therapeutics3 live mentions European Biotechnology Magazine3 live mentions Commercialise Senaparib Across2 live mentions MENA2 live mentions New Zealand2 live mentions China2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Pharmanovia.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.